Appraising Medical Trial Experiences of Ovarian Cancer Patients
Study Details
Study Description
Brief Summary
Historically, participation in clinical trials has been highly skewed towards specific demographic groups. However, research identifying which trial attributes impact participation, in either positive or negative ways, is limited. This study invites participants to record a wide range of data on their clinical trial experience, with the goal being to identify factors which persistently limit patients' ability to participate in, or complete, a trial in which they were initially interested. Data will be analyzed through a range of demographic lenses, in hopes of discovering patterns which might improve the experience of future ovarian cancer patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Patient decides to enroll in clinical trial [3 Months]
- Patient remains in clinical trial to completion [12 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
-
Patient has been diagnosed with ovarian cancer
-
Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination.
Exclusion Criteria:
-
Inability to perform regular electronic reporting
-
Patient does not understand, sign, and return consent form
-
Pregnant, breastfeeding or expecting to conceive within the projected duration of the study
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Power Life Sciences Inc.
Investigators
- Study Director: Michael B Gill, Power Life Sciences Inc.
Study Documents (Full-Text)
More Information
Publications
- Cho KR, Shih IeM. Ovarian cancer. Annu Rev Pathol. 2009;4:287-313. doi: 10.1146/annurev.pathol.4.110807.092246.
- Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. Ann Oncol. 2017 Nov 1;28(suppl_8):viii61-viii65. doi: 10.1093/annonc/mdx443.
- Previs RA, Secord AA. Ovarian Cancer: Clinical Trial Breakthroughs and Impact on Management. Obstet Gynecol Clin North Am. 2019 Mar;46(1):67-88. doi: 10.1016/j.ogc.2018.09.005.
- 89480700